Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies

被引:56
|
作者
Cohen, AD
Bonneh, DY
Reuveni, H
Vardy, DA
Naggan, L
Halevy, S
机构
[1] Soroka Univ, Dept Dermatol, Med Ctr, Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Clalit Hlth Serv, IL-84105 Beer Sheva, Israel
[3] Ben Gurion Univ Negev, Siaal Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel
[4] Ben Gurion Univ Negev, Epidemiol & Hlth Serv Evaluat Dept, IL-84105 Beer Sheva, Israel
[5] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
关键词
psoriasis vulgaris; drug reactions; angiotensin-converting enzyme inhibitors; beta-blockers; non-steroidal anti-inflammatory drugs;
D O I
10.1080/00015550510032823
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Intake of drugs is considered a risk factor for psoriasis. The aim of this study was to investigate the association between drugs and psoriasis. A case-control study including 110 patients who were hospitalized for extensive psoriasis was performed. A control group (n=515) was defined as patients who had undergone elective surgery. A case-crossover study included 98 patients with psoriasis. Exposure to drugs was assessed during a hazard period (3 months before hospitalization) and compared to a control period in the patient's past. Data on drug sales were extracted by data mining techniques. Multivariate analyses were performed by logistic regression and conditional logistic regression. In the case-control study, psoriasis was associated with benzodiazepines (OR 6.9), organic nitrates (OR 5.0), angiotensin-converting enzyme (ACE) inhibitors (OR 4.0) and non-steriodal anti-inflammatory drugs (NSAIDs) (OR 3.7). In the case-crossover study, psoriasis was associated with ACE inhibitors (OR 9.9), beta-blockers (OR 9.9), dipyrone (OR 4.9) and NSAIDs (OR 2.1). Extensive psoriasis may be associated with intake of ACE inhibitors, NSAIDs or beta-blockers.
引用
收藏
页码:299 / 303
页数:5
相关论文
共 50 条
  • [1] Differential misclassification of exposure in case-crossover studies
    Möller, J
    Hessén-Söderman, AC
    Hallqvist, J
    EPIDEMIOLOGY, 2004, 15 (05) : 589 - 596
  • [2] Pregabalin and injury: A nested case-control and case-crossover study
    Miyamoto, Yoshihisa
    Iwagami, Masao
    Aso, Shotaro
    Matsui, Hiroki
    Doi, Kent
    Yasunaga, Hideo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (05) : 558 - 564
  • [3] Case-crossover studies
    Künzli, N
    Schindler, C
    EPIDEMIOLOGY, 2005, 16 (04) : 592 - 593
  • [4] Case-crossover studies
    Lydersen, Stian
    Bjorngaard, Johan Hakon
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (03)
  • [5] Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan
    Murata, Kenji
    Onoyama, Sagano
    Yamamura, Kenichiro
    Mizuno, Yumi
    Furuno, Kenji
    Matsubara, Keita
    Hatae, Ken
    Masuda, Kiminori
    Nomura, Yuichi
    Ohno, Takuro
    Kinumaki, Akiko
    Miura, Masaru
    Sakai, Yasunari
    Ohga, Shouichi
    Fukushima, Wakaba
    Kishimoto, Junji
    Nakamura, Yosikazu
    Hara, Toshiro
    VACCINES, 2021, 9 (08)
  • [6] State anger and the risk of injury: A case-control and case-crossover study
    Vinson, DC
    Arelli, V
    ANNALS OF FAMILY MEDICINE, 2006, 4 (01) : 63 - 68
  • [7] Within-subject exposure dependency in case-crossover studies
    Vines, SK
    Farrington, CP
    STATISTICS IN MEDICINE, 2001, 20 (20) : 3039 - 3049
  • [8] Risk Factors for Seborrhoeic Dermatitis Flares: Case-control and Case-crossover Study
    Lancar, Remi
    Missy, Pascale
    Dupuy, Alain
    Beaulieu, Philippe
    Fardet, Laurence
    Costagliola, Dominique
    Chosidow, Olivier
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 5
  • [9] Confounding in case-crossover and case-time-control studies.
    Greenland, S
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1996, 143 (11) : 109 - 109
  • [10] A population-based case-crossover and case-control study of alcohol and the risk of injury
    Vinson, DC
    Maclure, M
    Reidinger, C
    Smith, GS
    JOURNAL OF STUDIES ON ALCOHOL, 2003, 64 (03): : 358 - 366